Canaccord raised the firm’s price target on Cipher Pharmaceuticals (CPHRF) to C$13 from C$12.50 and keeps a Hold rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPHRF:
- Cipher Pharmaceuticals Reports Strong Revenue Growth in Q1 2025
- Cipher Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Cipher Pharmaceuticals Reports Strong Q1 2025 Results and Strategic Debt Repayment
- CPHRF Upcoming Earnings Report: What to Expect?
- Cipher Pharmaceuticals to Announce Q1 2025 Financial Results